Patents by Inventor William T. Symonds
William T. Symonds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220409627Abstract: A method for treating an inflammatory disorder of the lower airways in a human subject in need thereof is described, including administering an effective amount of anakinra directly to the lower airways in the human subject; where the effective amount of anakinra is from about 0.1 mg to about 200 mg per day; and where the inflammatory disorder is selected from the group consisting of a toxic-inhalation lung injury, pulmonary langerhans cell histiocytosis, non-cystic fibrosis bronchiectasis, diffuse panbronchiolitis, acute respiratory distress syndrome (ARDS), reactive airways dysfunction syndrome (RADS), bronchiolitis obliterans organizing pneumonia and pneumonitis.Type: ApplicationFiled: December 2, 2020Publication date: December 29, 2022Inventors: Lyn A. BARANOWSKI, Brian A. LORTIE, James P. BISHOP, Kenneth S. KILGORE, William T. SYMONDS, Stephen A. WRING, Jayne E. HASTEDT, Katelyn R. CRIZER, Michelle PALACIOS
-
Publication number: 20170348342Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.Type: ApplicationFiled: January 19, 2017Publication date: December 7, 2017Inventors: Miriam Michelle Berrey, Melissa Jean Casteel, Darryl G. Cleary, Christy M. Hebner, Robert G. Hindes, Hongmei Mo, Reza Oliyai, Rowchanak Pakdaman, Adrian S. Ray, Charles J. Reynolds, Dimitrios Stefanidis, William T. Symonds, Vahid Zia
-
Patent number: 9549941Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.Type: GrantFiled: November 11, 2014Date of Patent: January 24, 2017Assignee: Gilead Pharmasset LLCInventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
-
Publication number: 20150150897Abstract: Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1.Type: ApplicationFiled: December 1, 2014Publication date: June 4, 2015Inventors: Jill M. Denning, John G. McHutchison, G. Mani Subramanian, William T. Symonds, III
-
Publication number: 20150150896Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.Type: ApplicationFiled: November 11, 2014Publication date: June 4, 2015Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
-
Patent number: 8889159Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.Type: GrantFiled: November 27, 2012Date of Patent: November 18, 2014Assignee: Gilead Pharmasset LLCInventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
-
Patent number: 8735345Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: GrantFiled: February 26, 2010Date of Patent: May 27, 2014Assignees: Hoffmann la Roche Inc., Pharmasset, Inc., Roche Palo Alto LLCInventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
-
Publication number: 20120128628Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: February 26, 2010Publication date: May 24, 2012Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
-
Publication number: 20120107278Abstract: Disclosed herein is a method for administering an abbreviated hepatitis C virus (HCV) treatment regimen for an HCV-infected, rs12979860 single nucleotide polymorphism (SNP) (C/C) patient, which comprises: administering to said patient an effective amount of each of a direct-acting antiviral, pegylated interferon alfa-2a, and ribavirin; wherein the abbreviated HCV treatment regimen is less than 48 weeks. Also disclosed herein is a method of detecting an rs12979860 single nucleotide polymorphism (SNP) in a hepatitis C virus (HCV) infected patient comprising: detecting the rs12979860 SNP of chromosome 19 in a biological sample from a patient, wherein an rs12979860 SNP C/C patient is administered an abbreviated treatment regimen with a direct-acting antiviral agent in combination with peginterferon alfa-2a and ribavirin; and wherein the abbreviated HCV treatment regimen is less than 48 weeks.Type: ApplicationFiled: October 31, 2011Publication date: May 3, 2012Applicant: Pharmasset, Inc.Inventors: MIRIAM MICHELLE BERREY, Peter Schaefer Price, JR., William T. Symonds
-
Publication number: 20100221217Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: February 26, 2010Publication date: September 2, 2010Applicants: InterMune, Inc., Roche Palo Alto LLC, Pharmasset, Inc.Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds